Volume 2.18 | May 20

Prostate Cell News 2.18, May 20, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY

Half of Prostate Cancers Could Potentially Benefit from New Type of Cancer Drugs
About half of prostate cancers have a genetic anomaly that appears to make tumor cells responsive to a new class of cancer-fighting drugs, a new study finds. [Press release from the University of Michigan Health System discussing online prepublication in Cancer Cell]

ON140_AldefluorOptimized_645x110

SCIENCE NEWS

Plasticity of Hormonal Response Permits Rapid Gene Expression Reprogramming
A new study reveals the unsuspected plasticity of some gene expression programs. Their findings show the existence of distinct regulated gene programs that can be alternatively induced, depending on the intracellular conditions. [Press release from the University of California, San Diego discussing online prepublication in Nature]

Coffee May Reduce Risk of Lethal Prostate Cancer in Men
Men who regularly drink coffee appear to have a lower risk of developing a lethal form of prostate cancer, according to a new study. [Press release from Harvard University School of Public Health discussing online prepublication in the Journal of the National Cancer Institute]

Phase III Data Demonstrate XGEVA™ (Denosumab) Is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men with Advanced Prostate Cancer
Amgen announced primary results of a pivotal Phase III trial (‘147) demonstrating that XGEVA™ significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone. [Press release from Amgen discussing research presented at the American Urological Association 2011 Annual Meeting]

Obesity Linked to Higher Risk of Prostate Cancer Progression
Even when treated with hormone therapy to suppress tumor growth, obese men face an elevated risk of their prostate cancer worsening, researchers have found. [Press release from Duke Health discussing research presented at the American Urological Association 2011 Annual Meeting]

When Rising PSA Means Prostate Cancer Is in Patient’s Future
A new study shows nearly 70 percent of men who had rising PSA levels and subsequent normal biopsies were eventually diagnosed with prostate cancer. [Press release from Northwestern University discussing research presented at the American Urological Association 2011 Annual Meeting]

Advanced-Stage Prostate Cancer Patients Experience 20-Year Survival Rates With Surgery, Mayo Clinic Long-Term Follow-Up Shows
A study has found a 20-year survival rate for 80 percent of patients diagnosed with cancer that has potentially spread beyond the prostate and treated with radical prostatectomy, or surgery to remove the prostate gland. [Press release from Mayo Clinic discussing research presented at the American Urological Association 2011 Annual Meeting]

ALDEFLUORCSC_645x110.jpg

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Reprogramming Transcription by Distinct Classes of Enhancers Functionally Defined by Enhancer-Templated Non-Coding RNA
Scientists present evidence that cell-lineage-specific factors, such as FoxA1, can simultaneously facilitate and restrict key regulated transcription factors, exemplified by the androgen receptor, to act on structurally and functionally distinct classes of enhancer. [Nature]

Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
Researchers investigated the mechanisms by which ETS fusions mediate their effects, and found that the product of the predominant ETS gene fusion, TMPRSS2:ERG, interacts in a DNA-independent manner with the enzyme poly (ADP-ribose) polymerase 1 and the catalytic subunit of DNA protein kinase. [Cancer Cell]

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Investigators found that androgen receptor (AR) transcriptional output is decreased in human and murine tumors with PTEN deletion and that PI3K pathway inhibition activates AR signaling by relieving feedback inhibition of HER kinases. [Cancer Cell]

Recurrent Chimeric RNAs Enriched in Human Prostate Cancer Identified by Deep Sequencing
By deep sequencing the transcriptome of 20 human prostate cancer and 10 matched benign prostate tissues, scientists obtained 1.3 billion sequence reads, which led to the identification of 2,369 chimeric RNA candidates. [Proc Natl Acad Sci U S A]

CCI-779 Inhibits Cell-Cycle G2/M Progression and Invasion of Castration-Resistant Prostate Cancer Via Attenuation of UBE2C Transcription and mRNA Stability
Researchers demonstrate that the G1/S cell-cycle inhibitor-779 (CCI-779), an mTOR inhibitor, inhibited UBE2C mRNA and protein expression in androgen receptor-positive castration-resistant prostate cancer cell models abl and C4-2B. [Cancer Res]

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations
This study aimed to clarify the biochemical and antitumor activity of CH5132799 and elucidate the correlation between CH5132799 response and genetic alterations in the phosphatidylinositol 3-kinase (PI3K) pathway. [Clin Cancer Res]

Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling
The aim of the present study was to identify novel methylation markers in prostate cancer (PCa) using microarray analysis, and to test whether those markers could discriminate normal and PCa cells. [Clin Cancer Res]

Characterization of the Oncogenic Activity of the Novel TRIM59 Gene in Mouse Cancer Models
Investigators identified two phosphorylated forms of TRIM59 (p53 and p55), and characterized them using purified TRIM59 proteins from mouse prostate cancer models at different stages with wild-type mice and NIH3T3 cells as controls. [Mol Cancer Ther]

Downregulation of Sec23A Protein by miRNA-375 in Prostate Carcinoma
Scientists demonstrate that the 3’UTR of the SEC23A mRNA is indeed a target for miR-375 and miR-200c, and that both microRNAs (miRNAs) down-regulate Sec23A protein expression when ectopically expressed in human 293T cells. [Mol Cancer Res]

CLINICAL RESEARCH

Coffee Consumption and Prostate Cancer Risk and Progression in the Health Professionals Follow-Up Study
Researchers observed a strong inverse association between coffee consumption and risk of lethal prostate cancer. The association appears to be related to non-caffeine components of coffee. [J Nat Cancer Inst]

A Large Cohort Study of Long-Term Acetaminophen Use and Prostate Cancer Incidence
Investigators examined the association between acetaminophen use and prostate cancer incidence among 78,485 men in the Cancer Prevention Study II Nutrition Cohort. [Cancer Epidemiol Biomarkers Prev]

INDUSTRY NEWS

Nuclea Discovery Could Significantly Improve Prostate Cancer Diagnosis, Treatment
Biomarker pioneer Nuclea Biotechnologies, Inc. released new research that could significantly alter and improve the way prostate cancer is diagnosed and treated. [Nuclea Biotechnologies, Inc. Press Release]

Advantagene Announces SPA Agreement with FDA to Launch Phase III Trial for Novel Vaccine Aimed at Preventing Prostate Cancer Recurrence
Advantagene, Inc. announced that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase III clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer. [Advantagene, Inc. Press Release]


Caris Life Sciences Presents Circulating Microvesicle Research Findings at American Urological Association Annual Meeting
Caris Life Sciences, Inc. presented a poster highlighting the potential of a circulating microvesicle-based prostate cancer test. [Caris Life Sciences, Inc. Press Release]

Dendreon Announces Presentation of PROVENGE Data at the 2011 American Society of Clinical Oncology Annual Meeting
Dendreon Corporation announced that a number of PROVENGE® (sipuleucel-T) data presentations will take place at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois. [Dendreon Corporation Press Release]

New Jersey Center for Prostate Cancer & Urology Among First in Nation to Treat Advanced Prostate Cancer Patients with PROVENGE
New Jersey Center for Prostate Cancer & Urology is among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies. [PR Newswire]

Pioneering Cancer Researcher Will Lead the New Duke Cancer Institute
Michael B. Kastan, MD, PhD has been named the executive director of the Duke Cancer Institute. [Duke Health Press Release]

POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS

NEW CIRM/Regenerative Medicine Consortium – Imaging Technology for Cellular Therapies
May 26, 2011
Webinar

NEW
Prostate Cancer Research Institute Conference 2011
September 9-11, 2011
Los Angeles, United States

Visit
our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES
Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine)

Postdoctoral Fellow (University of Houston – Center for Nuclear Receptors and Cell Signaling)

Assistant/Associate Research Scientist (New York University)

Postdoctoral Research Associate (Meharry Medical College)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us